Bacterial corneal ulcers in pediatric patients. Algorithms of pharmacotherapy. Part II

Abstract

Part I of the article presents a review of publications highlighting current exogenous and endogenous risk factors contributing to the occurrence of bacterial corneal ulcers, laboratory diagnostic methods, clinical differential diagnostic features of bacterial corneal ulcers.

A wide variety of objective symptoms characterizes the clinical picture of bacterial corneal ulcers. Still, objective differential diagnostic signs make it possible with a high degree of probability to assume the etiology of the disease during the first biomicroscopy and immediately begin etiotropic therapy, on the timing of which the outcome of the disease depends.

Standard laboratory examination of patients with bacterial corneal ulcers includes the bacterioscopic and cultural examination of the contents of the conjunctival sac. However, the absence of etiotropic therapy while waiting for the results of microbiological research methods, which takes from 3 to 7 days, contributes to the rapid progression of the disease, the development of endophthalmitis, and corneal perforation, up to the loss of an eye in children. In this regard, treatment must be started immediately. Therefore, the choice of a drug is determined not only by the causative agent, proven laboratory but, first of all, based on clinical differential diagnostic signs of the disease.

The traditional, undeniable approach to the conservative treatment of bacterial corneal ulcers is conventional etiotropic therapy using local and systemic antibacterial drugs. In addition, timely intensive specific drug therapy prevents the destruction of all layers of the cornea, and the use of metabolic drugs that improve regeneration and trophism promotes epithelialization of corneal ulcers.

Attention should be given to the necessity and validity of the choice of antibacterial drugs for various etiological forms of bacterial corneal ulcers in children. An individual approach is a basis for effective antibiotic therapy in pediatric ophthalmology.

The article presents an up-to-date review of publications and modern algorithms for treating bacterial corneal ulcers in children, the main causative agents of which are: Staphylococcus aureus, Streptococcus pneumoniae, Pseudomonas aeruginosa, Neisseria gonorrhoeae.

Keywords

bacterial corneal ulcers in pediatric patients / gonoblenorrhea / algorithms of pharmacotherapy / antibacterial medicinal agents / Staphylococcus aureus / Streptococcus pneumonia / Pseudomonas aeruginosa / Neisseria gonorrhoeae

References

[1] avo-portal.ru [Internet]. Neroev VV, Katargina LA, Yani EV, et al. Bakterial’nye yazvy rogovitsy. Federal’nye klinicheskie rekomendatsii. 2020. [cited 11 June 2021]. Available from: http://avo-portal.ru/doc/fkr/item/249-bakterialnye-yazvy-rogovitsy

[2] avo-portal.ru [интернет]. Нероев В.В., Катаргина Л.А., Яни Е.В., Вахова Е.С., и др. Бактериальные язвы роговицы. Федеральные клинические рекомендации, 2020 [дата обращения: 11.07.2021]. Доступ по ссылке: http://avo-portal.ru/doc/fkr/item/249-bakterialnye-yazvy-rogovitsy

[3] Neroev VV, Slepova OS, Kovaleva LA, Krichevskaya GI. Optimizing etiological diagnostics and improving the efficiency of treating centralized infectious corneal ulcers. Russian Ophthalmological Journal. 2017;10(3):56–61. (In Russ). doi: 10.21516/2072-0076-2017-10-3-56-61

[4] Нероев В.В., Слепова О.С., Ковалева Л.А., Кричевская Г.И. Оптимизация этиологической диагностики и повышение эффективности лечения инфекционных язв роговицы центральной локализации // Российский офтальмологический журнал. 2017. Т. 10, № 3. С. 56–61. doi: 10.21516/2072-0076-2017-10-3-56-61

[5] Kovaleva LA, Vakhova ЕS. Drug therapy algorithms in bacterial corneal ulcers. Effektivnaya farmakoterapiya. 2013;(23):46–48.

[6] Ковалева Л.А., Вахова Е.С. Алгоритмы фармакотерапии бактериальных язв роговицы // Эффективная фармакотерапия. Офтальмология. 2013. № 23. С. 46–48.

[7] Kasparova EA. Purulent corneal ulcers: clinical presentation, diagnosis, and conservative treatment. Vestnik oftal’mologii. 2015;131(6):106. doi: 10.17116/oftalma20151316106-119

[8] Каспарова Е. А. Гнойные язвы роговицы: клиника, диагностика, консервативное лечение // Вестник офтальмологии. 2015. Т. 131, № 6. С. 106–119. doi: 10.17116/oftalma20151316106-119

[9] Sitnik GV. Sovremennye podkhody k lecheniyu yazv rogovitsy. Medical Journal. 2007;22(4):100–104.

[10] Ситник Г.В. Современные подходы к лечению язв роговицы // Медицинский журнал. 2007. Т. 22, № 4. С. 100–104.

[11] Jain R, Murthy SI, Motukupally SR, Jain M. Use of topical colistin in multiple drug-resistant Pseudomonas aeruginosa bacterial keratitis. Cornea. 2014; 33(9):923–927.

[12] Jain R., Murthy S.I., Motukupally S.R., Jain M. Use of topical colistin in multiple drug-resistant Pseudomonas aeruginosa bacterial keratitis // Cornea. 2014. Vol. 33, N 9. Р. 923–927.

[13] Tajima K, Miyake T, Koike N, et al. In vivo challenging of polymyxins and levofloxacin eye drop against multidrug-resistant Pseudomonas aeruginosa keratitis. J Infect Chemother. 2014;20(6):343–349. doi: 10.1016/j.jiac.2013.10.015

[14] Tajima K., Miyake T., Koike N., et al. In vivo challenging of polymyxins and levofloxacin eye drop against multidrug-resistant Pseudomonas aeruginosa keratitis // J Infect Chemother. 2014. Vol. 20, N 6. P. 343–349. doi: 10.1016/j.jiac.2013.10.015

[15] Schmack I, Muller M, Kohnen T. [Microbial keratitis: Understand, recognize, and treat — part 1: General aspects and characteristics of bacterial keratitis]. Klin Monbl Augenheilkd. 2018;235(3):331–350. doi: 10.1055/s-0044-101286

[16] Schmack I., Muller M., Kohnen T. [Microbial keratitis: Understand, recognize, and treat — part 1: General aspects and characteristics of bacterial keratitis] // Klin Monbl Augenheilkd. 2018. Vol. 235, N 3. P. 331–350. doi: 10.1055/s-0044-101286

[17] McDonald EM, Ram FSF, Patel DV, McGhee CNJ. Topical antibiotics for the management of bacterial keratitis: an evidence-based review of high quality randomised controlled trials. British Journal of Ophthalmology. 2014;98(11):1470–1477. doi: 10.1136/bjophthalmol-2013-304660

[18] McDonald E.M., Ram F.S.F., Patel D.V., McGhee C.N.J. Topical antibiotics for the management of bacterial keratitis: an evidence-based review of high quality randomised controlled trials // British Journal of Ophthalmology. 2014. Vol. 98, N 11. P. 1470–1477. doi: 10.1136/bjophthalmol-2013-304660

[19] Segreti J, Jones RN, Bertino JS, Jr. Challenges in assessing microbial susceptibility and predicting clinical response to newer-generation fluoroquinolones. J Ocul Pharmacol Ther. 2012;28(1):3–11. doi: 10.1089/jop.2011.0072

[20] Segreti J., Jones R.N., Bertino J.S., Jr. Challenges in assessing microbial susceptibility and predicting clinical response to newer-generation fluoroquinolones // J Ocul Pharmacol Ther. 2012. Vol. 28, N 1. P. 3–11. doi: 10.1089/jop.2011.0072

[21] Kovaleva LA, Krichevskaya GI, Balackaya NV, Markelova OI. Treatment of corneal ulcers and endophthalmitis caused by yeast fungi. Russian Pediatric Ophthalmology. 2021;16(1):31–38. (In Russ). doi: 10.17816/rpo2021-16-1-31-38

[22] Ковалева Л.А., Кричевская Г.И., Балацкая Н.В., Маркелова О.И. Лечение язвы роговицы и эндофтальмита, вызванных дрожжевыми грибами // Российская педиатрическая офтальмология. 2021. Т. 16, №1. C. 31–38. doi: 10.17816/rpo2021-16-1-31–38

[23] avo-portal.ru [Internet]. Arestova NN, Brzheskii VV, Vakhova ES,et al. Kon”yunktivit. Federal’nye klinicheskie rekomendatsii, 2020 [cited 11 June 2021]. Available from: http://avo-portal.ru/doc/fkr/approved/item/351-kon’yunktivit

[24] avo-portal.ru [интернет]. Арестова Н.Н., Бржеский В.В., Вахова Е.С., и др. Конъюнктивит. Федеральные клинические рекомендации, 2020 [дата обращения: 11.07.2021]. Доступ по ссылке: http://avo-portal.ru/doc/fkr/approved/item/351-kon’yunktivit.

[25] Arestova NN, Katargina LA, Yani EV. Conjunctivitis and dacryocystitis in the children: the clinical characteristic and modern approaches to the treatment. Russian Pediatric Ophthalmology. 2016;11(4):200–206. (In Russ). doi: 10.18821/1993-1859-2016-11-4-200-206

[26] Арестова Н.Н., Катаргина Л.А., Яни Е.В. Конъюнктивиты и дакриоциститы у детей: клиническая характеристика, современные возможности лечения // Российская педиатрическая офтальмология. 2016. Т. 11, № 4. С. 200–206. doi.org/10.18821/1993-1859-2016-11-4-200-206

[27] medi.ru [Internet]. Kubanova AA, Kubanov AA, Rakhmatulina MR, et al. Gonokokkovaya infektsiya. Klinicheskie rekomendatsii, 2020 [cited 11 June 2021]. Available from: https://medi.ru/klinicheskie-rekomendatsii/gonokokkovaya-infektsiya_13986/

[28] medi.ru [интернет]. Кубанова А.А., Кубанов А.А., Рахматулина М.Р., и др. Гонококковая инфекция. Клинические рекомендации, 2020 [дата обращения: 11.07.2021]. Доступ по ссылке: https://medi.ru/klinicheskie-rekomendatsii/gonokokkovaya-infektsiya_13986/

[29] Kubanova AA. Vedenie bol’nykh s infektsiyami, peredavaemymi polovym putem, i urogenital’nymi infektsiyami: Klinicheskie rekomendatsii. Rossiiskoe obshchestvo dermatovenerologov i kosmetologov. Мoscow: Delovoj ekspress; 2012.

[30] Кубанова А.А. Ведение больных с инфекциями, передаваемыми половым путём, и урогенитальными инфекциями: Клинические рекомендации. Российское общество дерматовенерологов и косметологов. М.: Деловой экспресс, 2012. 112 с.

[31] Rahmatulina MR. Gonococcal infection in minors: social-epidemiological features and the analysis of the antibiotic resistance level in N. Gonorrhoeae. Vestnik dermatologii i venerologii. 2008;(1):51–53.

[32] Рахматулина М.Р. Гонококковая инфекция у несовершеннолетних: социально-эпидемиологические особенности и анализ уровня антибиотикорезистентности N. Gonorrhoeae // Вестник дерматологии и венерологии. 2008. № 1. С.51–53.

[33] Workowski KA, Berman S, Centers for Disease C, Prevention. Sexually transmitted diseases treatment guidelines, 2010. MMWR Recomm Rep. 2010;59(RR-12):1–110.

[34] Workowski K.A., Berman S., Centers for Disease C., Prevention. Sexually transmitted diseases treatment guidelines, 2010 // MMWR Recomm Rep. 2010. Vol. 59, N RR-12. P. 1–110.

[35] cdc.gov [Internet]. CDC. Sexually Transmitted Diseases Surveillance 2012 Atlanta: US Department of Health and Human Services; 2015 [cited 11 June 2021]. Available from: http://www.cdc.gov/std/tg2015/gonorrhea.htm.

[36] cdc.gov [интернет] CDC. Sexually Transmitted Diseases Surveillance 2012 Atlanta: US Department of Health and Human Services; 2015 [дата обращения: 11.07.2021]. Доступ по ссылке: http://www.cdc.gov/std/tg2015/gonorrhea.htm.

[37] cdc.gov [Internet]. CDC. Sexually Transmitted Diseases Treatment Guidelines, 2015 MMWR/June 5, 2015/Vol. 64/No. 3 [cited 11 June 2021]. Available from: https://www.cdc.gov/mmwr/pdf/rr/rr6403.pdf

[38] cdc.gov [интернет] CDC. Sexually Transmitted Diseases Treatment Guidelines, 2015 MMWR/June 5, 2015/Vol. 64/No. 3 [дата обращения: 11.07.2021]. Доступ по ссылке: https://www.cdc.gov/mmwr/pdf/rr/rr6403.pdf

[39] MacDonald N, Mailman T, Desai S. Gonococcal infections in newborns and in adolescents. Adv Exp Med Biol. 2008;609:108–130. doi: 10.1007/978-0-387-73960-1_9

[40] MacDonald N., Mailman T., Desai S. Gonococcal infections in newborns and in adolescents // Adv Exp Med Biol. 2008. Vol. 609, P. 108–130. doi: 10.1007/978-0-387-73960-1_9

RIGHTS & PERMISSIONS

Eco-Vector